Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06517004 | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT03832127 | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients(Myelofludate) | recruiting | Phase 1 | 35 | Nantes University HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06445803 | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | recruiting | Phase 1 | 48 | Rong TaoOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)(CARMA-01) | recruiting | Phase 1 / Phase 2 | 18 | Uppsala UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05869279 | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 29 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | recruiting | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06252298 | A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies | recruiting | Phase 1 | 74 | Sinocelltech Ltd.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL(AETHER) | recruiting | Phase 1 / Phase 2 | 112 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Apr 12, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06321289 | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04243785 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 80 | Edgewood Oncology Inc.INDUSTRY | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06232096 | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. | recruiting | Phase 1 / Phase 2 | 154 | Beijing Mabworks Biotech Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06246162 | Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 75 | Sheba Medical CenterOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06225856 | An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 96 | Shanghai Yuyao Biotech Co., Ltd.INDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06196255 | Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05675813 | Genotype-guided Treatment in Newly Diagnosed PTCL(THEORY) | recruiting | Phase 1 / Phase 2 | 264 | Ruijin HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06180174 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | recruiting | Phase 1 | 24 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | recruiting | Phase 1 | 9 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06132711 | Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | recruiting | Phase 1 | 134 | OncotherapeuticsINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05573802 | A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | Hellenic Society of HematologyOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05230680 | Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | recruiting | Phase 1 / Phase 2 | 41 | Won Seog KimOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06084962 | A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | recruiting | Phase 1 | 40 | He HuangOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05768529 | Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05948033 | CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05842707 | Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 48 | Aibin Liang,MD,Ph.D.OTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04959903 | Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT | recruiting | Phase 1 / Phase 2 | 36 | Smart Immune SASINDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05682755 | Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT | recruiting | Phase 1 / Phase 2 | 77 | Sichuan UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT03161223 | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | recruiting | Phase 1 / Phase 2 | 148 | University of VirginiaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05043571 | CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | recruiting | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT04771507 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)(IbruOnOff) | recruiting | Phase 1 / Phase 2 | 50 | Jeanette LundinOTHER | 2 | Feb 25, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2024source: clinicaltrials